Oral immune-related adverse events in patients with and without inflammatory bowel disease receiving immune checkpoint inhibitor therapy
Inflammatory Bowel Diseases · 2026-11-02
DOI: 10.1093/ibd/izag195 ↗Abstract
Abstract Background Immune checkpoint inhibitors (ICIs) are associated with oral immune-related adverse events (irAEs). We sought to determine whether mucosal immune dysregulation in inflammatory bowel disease (IBD) predisposes patients to a higher risk or severity of these toxic effects. Methods This retrospective cohort study evaluated adult cancer patients treated with ICIs at a tertiary cancer center between 2012 and 2024. Patients who developed oral irAEs within 1 year of starting ICIs were stratified by IBD status; IBD patients were matched 1:2 with non-IBD patients based on age, sex, and cancer type. We retrieved clinical information from electronic health records. Results Of 450 patients treated with ICIs, 152 had pre-existing IBD. Patients with IBD had a longer median time to oral lesion onset. Oral mucosal toxic effects were significantly less frequent, and symptoms such as xerostomia, dysgeusia, mucositis, dysphagia, and oral candidiasis were all significantly lower in IBD patients. Severity grades for mucositis, oral pain, and dysphagia were similar between groups. Supportive care for oral irAEs was used less often in the IBD group. Hospitalizations due to oral lesions were rare, and ICI therapy was paused in similar proportions between groups. Recurrence of oral lesions was less frequent in IBD patients. Conclusion Patients with IBD who receive ICIs were less likely to develop oral irAEs than those without IBD, possibly due to the protective effects of concurrent IBD therapies initiated before or during ICI treatment. These results highlight the feasibility and tolerability of ICI therapy in patients with IBD.
EUVIMED